Company Profile
Y-mAbs Stock Price, News & Catalysts
- Ticker:
- YMAB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for YMAB.
Company overview
Business overview
Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Y-mAbs sits in specialty biotechnology.
Business Model Characteristics
The company depends on product adoption, clinical progress, and the expansion of its antibody franchise.
Position Within the Biotechnology Landscape
Y-mAbs is a focused antibody biotech whose stock reacts to data, adoption, and label progress.
Future catalysts
- Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update. The key question is whether the GD2 franchise can keep compounding.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Y-mAbs do?
Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.
On which exchange is YMAB stock listed?
Y-mAbs (YMAB) is associated with NASDAQ, United States, Biopharma.
What is Y-mAbs?
Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update.
Which conditions is Y-mAbs targeting with Y-mAbs?
Y-mAbs is associated with oncology based on its company overview and current catalyst commentary.
How does Y-mAbs describe recent progress with Y-mAbs?
Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update.
What is Therapeutics?
Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies.
What should investors watch for with Therapeutics?
Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update. The key question is whether the GD2 franchise can keep compounding.
What future catalysts are investors watching for Y-mAbs?
Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update. The key question is whether the GD2 franchise can keep compounding.